科多诺普西斯 (Codonopsis pilosula polysaccharide) 通过调节肠道微生物群和SCFA/GPR/NLRP3通路来缓解性结肠炎
Jiaxin Zhou1, Qixin Yang1, Wenfeng Wei2
1School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China; Guangdong Provincial Key Laboratory of Chinese Medicine, Pharmaceutics, Guangzhou, 510515, China.
Journal of ethnopharmacology
|October 11, 2024
概括
科多诺普西斯 (Codonopsis pilosula polysaccharide,简称CPPS) 通过调节肠道微生物群和通过SCFA/GPR/NLRP3通路抑制炎症,有效治疗性结肠炎 (UC). 这项研究澄清了CPPS的情况.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- (Codonopsis pilosula) 是一种传统的中国草药,用于治疗性结肠炎 (UC).
- C. pilosula 聚糖 (CPPS) 是一种关键的生物活性成分,与肠道微生物群相互作用,产生治疗效果.
- 通过肠道微生物群调节在UC治疗中CPPS的确切机制尚不清楚.
研究的目的:
- 在小鼠中研究CPPS对硫酸 (DSS) 诱导的UC的治疗疗效.
- 阐明CPPS作用的潜在机制,重点关注肠道微生物群调节和炎症途径.
主要方法:
- 分析了CPPS分子量和单糖组成.
- 通过使用DSS管理建立了UC的小鼠模型.
- 评估了CPPS的治疗效果,包括炎症性细胞因子水平,组织病理学,肠道微生物群组成和短链脂肪酸 (SCFA) 生产.
- 研究了G蛋白结合受体 (GPR) /核酸结合寡聚化域类受体蛋白3 (NLRP3) 途径.
- 便微生物群移植 (FMT) 用于确认肠道微生物群的作用.
主要成果:
- 治疗CPPS显著缓解了DSS诱导的UC症状.
- CPPS调节了肠道微生物群,增加了Firmicutes/Bacteroidetes的比率和有益细菌的丰富性 (例如,Ligilactobacillus,Akkermansia).
- 通过将SCFA与GPR蛋白结合,CPPS促进了SCFA (酸和黄油酸) 的产生,并抑制了NLRP3的激活,从而减少了结肠炎症.
- FMT实验证实,CPPS改变的肠道微生物群可以减轻UC症状.
结论:
- CPPS在UC上显示出显著的治疗效果.
- 肠道微生物群调节和SCFA/GPR/NLRP3通路是CPPS在UC中的抗炎作用的关键机制.
- CPPS是性结肠炎治疗的有前途的治疗候选者.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
01:29Drugs for Treatment of Ulcerative Colitis in IBD
126
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
126
01:17Drugs for Treatment of Diarrhea-Predominant IBS
151
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
151
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
323
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
147
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
147
01:17Chronic Bowel Disorders: Introduction
397
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
397